Envista Holdings (NVST)
Envista Holdings on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as dental equipment & supplies.
12.1M
Short interest
settlement 2026-09-30
3.6
Days to cover
-0.4 days vs prior
43.1%
Short share of volume
2026-10-23
4,741
Fails to deliver
settlement 2026-09-25
Wed 28 Oct
Next earnings
estimated date
-$220K
Insider flow, 90 days
0 buys, 1 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in NVST is 12,072,597 shares, up 690,417 shares over the last month. Over the last 48 readings it ranged from 7,296,729 shares (13 March 2026) to 15,385,127 shares (15 October 2024). At the reported average volume of 3.4M shares a day that is 3.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/nvst" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 12,072,597 | +18.2% | 3,380,728 | 3.57 |
| 2026-09-15 | 10,210,406 | -10.3% | 2,573,767 | 3.97 |
| 2026-08-31 | 11,382,180 | +18.1% | 2,072,884 | 5.49 |
| 2026-08-14 | 9,634,725 | -19.0% | 3,670,693 | 2.62 |
| 2026-07-31 | 11,888,831 | +27.0% | 2,562,354 | 4.64 |
| 2026-07-15 | 9,360,613 | -4.8% | 2,784,264 | 3.36 |
| 2026-06-30 | 9,836,917 | -18.7% | 2,717,701 | 3.62 |
| 2026-06-15 | 12,104,216 | +2.2% | 2,612,655 | 4.63 |
| 2026-05-29 | 11,848,235 | +3.8% | 4,337,516 | 2.73 |
| 2026-05-15 | 11,412,631 | +20.9% | 4,182,007 | 2.73 |
| 2026-04-30 | 9,441,087 | -14.3% | 2,379,227 | 3.97 |
| 2026-04-15 | 11,022,995 | +13.7% | 2,016,250 | 5.47 |
| 2026-03-31 | 9,691,732 | +32.8% | 2,379,616 | 4.07 |
| 2026-03-13 | 7,296,729 | -2.9% | 2,503,544 | 2.91 |
| 2026-02-27 | 7,515,894 | -5.7% | 2,732,375 | 2.75 |
| 2026-02-13 | 7,966,257 | -1.5% | 4,999,094 | 1.59 |
| 2026-01-30 | 8,087,163 | -23.3% | 2,580,648 | 3.13 |
| 2026-01-15 | 10,544,812 | +0.9% | 2,405,622 | 4.38 |
| 2025-12-31 | 10,445,519 | +7.0% | 2,173,387 | 4.81 |
| 2025-12-15 | 9,762,837 | -7.8% | 2,323,946 | 4.20 |
| 2025-11-28 | 10,583,006 | -1.7% | 1,654,645 | 6.40 |
| 2025-11-14 | 10,763,980 | +0.0% | 2,069,739 | 5.20 |
| 2025-10-31 | 10,762,592 | +4.9% | 2,287,953 | 4.70 |
| 2025-10-15 | 10,258,965 | +12.7% | 2,026,019 | 5.06 |
| 2025-09-30 | 9,100,670 | -11.2% | 2,178,120 | 4.18 |
| 2025-09-15 | 10,246,358 | +5.8% | 1,587,807 | 6.45 |
| 2025-08-29 | 9,681,986 | -6.1% | 1,476,877 | 6.56 |
| 2025-08-15 | 10,312,846 | +9.8% | 2,650,078 | 3.89 |
| 2025-07-31 | 9,396,515 | -14.5% | 2,599,222 | 3.62 |
| 2025-07-15 | 10,991,379 | -0.3% | 1,932,047 | 5.69 |
| 2025-06-30 | 11,030,003 | +8.5% | 2,014,464 | 5.48 |
| 2025-06-13 | 10,165,707 | -1.5% | 1,777,979 | 5.72 |
| 2025-05-30 | 10,319,510 | +11.1% | 3,009,908 | 3.43 |
| 2025-05-15 | 9,286,325 | -15.4% | 2,738,822 | 3.39 |
| 2025-04-30 | 10,971,699 | -3.1% | 2,584,255 | 4.25 |
| 2025-04-15 | 11,323,958 | +18.3% | 3,573,012 | 3.17 |
| 2025-03-31 | 9,573,772 | +17.7% | 4,041,417 | 2.37 |
| 2025-03-14 | 8,131,989 | -4.8% | 3,163,026 | 2.57 |
| 2025-02-28 | 8,543,186 | -12.5% | 2,176,294 | 3.93 |
| 2025-02-14 | 9,760,306 | -4.7% | 2,794,187 | 3.49 |
| 2025-01-31 | 10,237,081 | -5.6% | 1,936,285 | 5.29 |
| 2025-01-15 | 10,846,647 | -13.8% | 1,806,031 | 6.01 |
| 2024-12-31 | 12,575,750 | +12.2% | 2,134,391 | 5.89 |
| 2024-12-13 | 11,213,330 | +0.1% | 1,942,750 | 5.77 |
| 2024-11-29 | 11,207,651 | -2.7% | 1,753,559 | 6.39 |
| 2024-11-15 | 11,519,106 | -6.1% | 1,977,968 | 5.82 |
| 2024-10-31 | 12,267,857 | -20.3% | 2,469,060 | 4.97 |
| 2024-10-15 | 15,385,127 | -14.8% | 1,862,552 | 8.26 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 23 October 2026, the short share of NVST volume is 43.1%, down 34.3 points over the last five sessions. Over the last 30 readings it ranged from 37.2% (21 October 2026) to 80.9% (16 September 2026). The latest reading is 18.0 points below the 30-session average of 61.1%, on 1.1M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 475K | 1.1M | 43.1% | 0 |
| 2026-10-22 | 819K | 1.5M | 53.1% | 25 |
| 2026-10-21 | 890K | 2.4M | 37.2% | 774 |
| 2026-10-20 | 1.2M | 2.5M | 47.9% | 0 |
| 2026-10-19 | 800K | 1.0M | 79.3% | 0 |
| 2026-10-16 | 623K | 804K | 77.4% | 0 |
| 2026-10-15 | 1.2M | 1.6M | 72.8% | 3,306 |
| 2026-10-14 | 359K | 726K | 49.4% | 0 |
| 2026-10-13 | 556K | 933K | 59.6% | 0 |
| 2026-10-12 | 458K | 1.0M | 43.9% | 0 |
| 2026-10-09 | 522K | 881K | 59.2% | 1 |
| 2026-10-08 | 471K | 895K | 52.6% | 1,816 |
| 2026-10-07 | 418K | 712K | 58.8% | 557 |
| 2026-10-06 | 368K | 616K | 59.7% | 0 |
| 2026-10-05 | 497K | 779K | 63.8% | 0 |
| 2026-10-02 | 586K | 938K | 62.5% | 0 |
| 2026-10-01 | 479K | 829K | 57.8% | 24,900 |
| 2026-09-30 | 371K | 605K | 61.3% | 0 |
| 2026-09-29 | 991K | 1.4M | 71.2% | 4 |
| 2026-09-28 | 521K | 890K | 58.6% | 257 |
| 2026-09-25 | 945K | 1.3M | 70.5% | 0 |
| 2026-09-24 | 667K | 1.1M | 62.4% | 0 |
| 2026-09-23 | 654K | 1.0M | 62.7% | 0 |
| 2026-09-22 | 995K | 1.8M | 56.3% | 0 |
| 2026-09-21 | 751K | 1.2M | 64.0% | 2 |
| 2026-09-18 | 989K | 1.4M | 72.1% | 350 |
| 2026-09-17 | 1.3M | 1.9M | 70.2% | 593 |
| 2026-09-16 | 1.2M | 1.5M | 80.9% | 0 |
| 2026-09-15 | 1.4M | 1.9M | 73.3% | 229 |
| 2026-09-14 | 490K | 930K | 52.7% | 31,912 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 25 September 2026, the fails-to-deliver balance in NVST is 4,741 shares, up 4,514 shares over the last settlement date. Over the last 30 readings it ranged from 18 shares (30 June 2026) to 37,946 shares (28 August 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-25 | 4,741 | $24.07 | $114K |
| 2026-09-23 | 227 | $24.18 | $5K |
| 2026-09-21 | 99 | $23.35 | $2K |
| 2026-09-18 | 58 | $23.69 | $1K |
| 2026-09-17 | 4,993 | $24.97 | $125K |
| 2026-09-16 | 188 | $24.73 | $5K |
| 2026-09-14 | 855 | $25.55 | $22K |
| 2026-09-09 | 224 | $26.81 | $6K |
| 2026-09-02 | 1,315 | $26.64 | $35K |
| 2026-09-01 | 21,090 | $27.14 | $572K |
| 2026-08-28 | 37,946 | $27.44 | $1.0M |
| 2026-08-27 | 132 | $27.80 | $4K |
| 2026-08-17 | 1,432 | $28.07 | $40K |
| 2026-08-11 | 87 | $28.19 | $2K |
| 2026-08-07 | 52 | $27.38 | $1K |
| 2026-07-23 | 443 | $26.43 | $12K |
| 2026-07-14 | 236 | $26.22 | $6K |
| 2026-07-02 | 3,121 | $27.17 | $85K |
| 2026-07-01 | 3,117 | $26.35 | $82K |
| 2026-06-30 | 18 | $27.02 | $486 |
| 2026-06-25 | 184 | $26.04 | $5K |
| 2026-06-24 | 805 | $25.26 | $20K |
| 2026-06-23 | 34,868 | $25.51 | $889K |
| 2026-06-22 | 937 | $25.91 | $24K |
| 2026-06-18 | 336 | $24.86 | $8K |
| 2026-06-11 | 220 | $24.06 | $5K |
| 2026-06-05 | 3,034 | $22.87 | $69K |
| 2026-06-01 | 25 | $23.55 | $589 |
| 2026-05-28 | 69 | $23.31 | $2K |
| 2026-05-18 | 35 | $23.22 | $813 |
Insider trades
SEC Form 4, newest first. JSONInsiders at NVST reported 1 open-market sell worth $220K in the last 90 days and no open-market buys. Latest filing: Nilsson Stefan (President, Nobel Biocare) on 2026-08-25.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-25 | Nilsson Stefan | President, Nobel Biocare | Tax withholding | 804 | $27.47 | $22K | 62K |
| 2026-08-25 | Hammes Eric D. | Chief Financial Officer | Tax withholding | 11K | $27.47 | $299K | 100K |
| 2026-08-25 | Befidi Robert | President, Diagnostics | Tax withholding | 5K | $27.47 | $141K | 46K |
| 2026-08-25 | Acurio Veronica | President, Orthodontics | Tax withholding | 8K | $27.47 | $212K | 49K |
| 2026-08-20 | Reis Mischa | SVP, Strategy & Bus. Dev. | Sell | 8K | $27.50 | $220K | 27K |
| 2026-08-18 | Keel Paul A | Chief Executive Officer | Grant | 180K | $0.00 | $0 | 551K |
| 2026-05-25 | Keel Paul A | Chief Executive Officer | Tax withholding | 13K | $23.43 | $300K | 372K |
| 2026-05-19 | Pierce James Andrew | Director | Grant | 9K | $0.00 | $0 | 18K |
| 2026-05-19 | Jain Vivek | Director | Grant | 9K | $0.00 | $0 | 53K |
| 2026-05-19 | Huennekens R Scott | Director | Grant | 13K | $0.00 | $0 | 82K |
| 2026-05-19 | GALLAHUE KIERAN | Director | Grant | 9K | $0.00 | $0 | 54K |
| 2026-05-19 | Raskas Daniel | Director | Grant | 9K | $0.00 | $0 | 54K |
| 2026-05-19 | TSINGOS CHRISTINE A | Director | Grant | 9K | $0.00 | $0 | 60K |
| 2026-05-19 | Carruthers Wendy | Director | Grant | 9K | $0.00 | $0 | 60K |
| 2026-02-25 | Nilsson Stefan | President, Nobel Biocare | Grant | 8K | $0.00 | $0 | 62K |
| 2026-02-25 | Nilsson Stefan | President, Nobel Biocare | Tax withholding | 182 | $29.59 | $5K | 55K |
| 2026-02-25 | Kaabi Faez C | Chief Accounting Officer | Grant | 14K | $0.00 | $0 | 59K |
| 2026-02-25 | Kaabi Faez C | Chief Accounting Officer | Tax withholding | 5K | $29.59 | $147K | 45K |
| 2026-02-25 | Reis Mischa | SVP, Strategy & Bus. Dev. | Grant | 6K | $0.00 | $0 | 35K |
| 2026-02-25 | Reis Mischa | SVP, Strategy & Bus. Dev. | Tax withholding | 3K | $29.59 | $88K | 29K |
| 2026-02-25 | Nance Mark E | General Counsel | Grant | 13K | $0.00 | $0 | 81K |
| 2026-02-25 | Nance Mark E | General Counsel | Tax withholding | 3K | $29.59 | $100K | 69K |
| 2026-02-25 | Keel Paul A | Chief Executive Officer | Grant | 49K | $0.00 | $0 | 384K |
| 2026-02-25 | Keel Paul A | Chief Executive Officer | Tax withholding | 12K | $29.59 | $350K | 336K |
| 2026-02-25 | Hammes Eric D. | Chief Financial Officer | Grant | 16K | $0.00 | $0 | 111K |
| 2026-02-25 | Hammes Eric D. | Chief Financial Officer | Tax withholding | 2K | $29.59 | $61K | 95K |
| 2026-02-25 | Befidi Robert | President, Diagnostics | Grant | 8K | $0.00 | $0 | 51K |
| 2026-02-25 | Befidi Robert | President, Diagnostics | Tax withholding | 2K | $29.59 | $64K | 43K |
| 2026-02-25 | Acurio Veronica | President, Orthodontics | Grant | 8K | $0.00 | $0 | 57K |
| 2026-02-25 | Acurio Veronica | President, Orthodontics | Tax withholding | 1K | $29.59 | $42K | 49K |
| 2026-02-10 | Reis Mischa | SVP, Strategy & Bus. Dev. | Sell | 6K | $30.00 | $169K | 32K |
| 2026-02-10 | Reis Mischa | SVP, Strategy & Bus. Dev. | Exercise or conversion | 6K | $15.97 | $90K | 38K |
| 2026-02-10 | Reis Mischa | SVP, Strategy & Bus. Dev. | Sell | 4K | $30.00 | $121K | 32K |
| 2026-02-10 | Reis Mischa | SVP, Strategy & Bus. Dev. | Exercise or conversion | 4K | $19.04 | $77K | 36K |
| 2025-11-01 | Keel Paul A | Chief Executive Officer | Tax withholding | 54K | $20.35 | $1.1M | 348K |
| 2025-08-25 | Nilsson Stefan | President, Nobel Biocare | Tax withholding | 804 | $21.12 | $17K | 55K |
| 2025-08-25 | Reis Mischa | SVP, Strategy & Bus. Dev. | Sell | 15K | $21.60 | $324K | 32K |
| 2025-08-25 | Hammes Eric D. | Chief Financial Officer | Tax withholding | 8K | $21.12 | $162K | 97K |
| 2025-08-25 | Befidi Robert | President, Diagnostics | Tax withholding | 3K | $21.12 | $73K | 46K |
| 2025-08-25 | Acurio Veronica | President, Orthodontics | Tax withholding | 5K | $21.12 | $115K | 50K |
| 2025-07-14 | Pierce James Andrew | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2025-06-10 | GALLAHUE KIERAN | Director | Grant | 10K | $0.00 | $0 | 45K |
| 2025-06-10 | Raskas Daniel | Director | Grant | 10K | $0.00 | $0 | 45K |
| 2025-06-10 | Jain Vivek | Director | Grant | 10K | $0.00 | $0 | 44K |
| 2025-06-10 | TSINGOS CHRISTINE A | Director | Grant | 10K | $0.00 | $0 | 51K |
| 2025-06-10 | Hulit Barbara B. | Director | Grant | 10K | $0.00 | $0 | 80K |
| 2025-06-10 | Huennekens R Scott | Director | Grant | 14K | $0.00 | $0 | 70K |
| 2025-06-10 | Carruthers Wendy | Director | Grant | 10K | $0.00 | $0 | 51K |
| 2025-05-25 | Keel Paul A | Chief Executive Officer | Tax withholding | 13K | $16.72 | $214K | 402K |
| 2025-02-26 | Reis Mischa | SVP, Strategy & Bus. Dev. | Grant | 8K | $0.00 | $0 | 47K |
| 2025-02-25 | Nance Mark E | General Counsel | Tax withholding | 4K | $20.66 | $76K | 54K |
| 2025-02-25 | Nance Mark E | General Counsel | Grant | 18K | $0.00 | $0 | 72K |
| 2025-02-25 | Hammes Eric D. | Chief Financial Officer | Grant | 16K | $0.00 | $0 | 104K |
| 2025-02-25 | Befidi Robert | President, Diagnostics | Grant | 10K | $0.00 | $0 | 49K |
| 2025-02-25 | Befidi Robert | President, Diagnostics | Tax withholding | 1K | $20.66 | $23K | 39K |
| 2025-02-25 | Nilsson Stefan | President, Nobel Biocare | Grant | 10K | $0.00 | $0 | 56K |
| 2025-02-25 | Acurio Veronica | President, Orthodontics | Grant | 10K | $0.00 | $0 | 56K |
| 2025-02-25 | Keel Paul A | Chief Executive Officer | Grant | 66K | $0.00 | $0 | 414K |
| 2025-02-25 | Reis Mischa | SVP, Strategy & Bus. Dev. | Tax withholding | 4K | $20.66 | $79K | 39K |
| 2025-02-25 | Kaabi Faez C | Chief Accounting Officer | Tax withholding | 4K | $20.66 | $89K | 40K |
| 2025-02-25 | Kaabi Faez C | Chief Accounting Officer | Grant | 10K | $0.00 | $0 | 50K |
| 2024-11-01 | Keel Paul A | Chief Executive Officer | Tax withholding | 54K | $20.94 | $1.1M | 349K |
| 2024-09-17 | Reis Mischa | SVP, Strategy & Bus. Dev. | Tax withholding | 812 | $19.00 | $15K | 43K |
| 2024-08-25 | Hammes Eric D. | Chief Financial Officer | Grant | 64K | $0.00 | $0 | 89K |
| 2024-08-25 | Befidi Robert | President, Diagnostics | Tax withholding | 3K | $18.70 | $65K | 40K |
| 2024-08-13 | Keel Paul A | Chief Executive Officer | Buy | 30K | $16.87 | $506K | 403K |
| 2024-08-12 | Hammes Eric D. | Chief Financial Officer | Buy | 25K | $16.33 | $401K | 25K |
| 2024-07-15 | Nance Mark E | General Counsel | Tax withholding | 491 | $15.94 | $8K | 57K |
| 2024-06-25 | Keller Stephen | Principal Financial Officer | Grant | 31K | $0.00 | $0 | 54K |
| 2024-05-25 | Keel Paul A | Chief Executive Officer | Grant | 301K | $0.00 | $0 | 373K |
| 2024-05-25 | Keel Paul A | Chief Executive Officer | Grant | 71K | $0.00 | $0 | 71K |
| 2024-05-25 | Conley Eric | SVP, Orthodontics | Tax withholding | 642 | $18.25 | $12K | 53K |
| 2024-05-21 | TSINGOS CHRISTINE A | Director | Grant | 10K | $0.00 | $0 | 40K |
| 2024-05-21 | Jain Vivek | Director | Grant | 10K | $0.00 | $0 | 33K |
| 2024-05-21 | Huennekens R Scott | Director | Grant | 14K | $0.00 | $0 | 55K |
| 2024-05-21 | Hulit Barbara B. | Director | Grant | 10K | $0.00 | $0 | 69K |
| 2024-05-21 | Raskas Daniel | Director | Grant | 10K | $0.00 | $0 | 34K |
| 2024-05-21 | Carruthers Wendy | Director | Grant | 10K | $0.00 | $0 | 40K |
| 2024-05-21 | GALLAHUE KIERAN | Director | Grant | 10K | $0.00 | $0 | 34K |
| 2024-04-15 | Hulit Barbara B. | Director | Grant | 13K | $0.00 | $0 | 59K |
| 2024-03-15 | Hulit Barbara B. | Director | Grant | 12K | $0.00 | $0 | 46K |
| 2024-02-25 | Aghdaei Amir | Chief Executive Officer | Grant | 49K | $0.00 | $0 | 311K |
| 2024-02-25 | Aghdaei Amir | Chief Executive Officer | Tax withholding | 33K | $22.65 | $756K | 262K |
| 2024-02-25 | Conley Eric | SVP, Orthodontics | Grant | 8K | $0.00 | $0 | 54K |
| 2024-02-25 | Conley Eric | SVP, Orthodontics | Tax withholding | 1K | $22.65 | $28K | 46K |
| 2024-02-25 | Befidi Robert | President, Diagnostics | Grant | 9K | $0.00 | $0 | 43K |
| 2024-02-25 | Reis Mischa | SVP, Strategy & Bus. Dev. | Grant | 17K | $0.00 | $0 | 44K |
| 2024-02-25 | Reis Mischa | SVP, Strategy & Bus. Dev. | Tax withholding | 4K | $22.65 | $94K | 27K |
| 2024-02-25 | Keller Stephen | Principal Financial Officer | Grant | 11K | $0.00 | $0 | 23K |
| 2024-02-25 | Keller Stephen | Principal Financial Officer | Tax withholding | 2K | $22.65 | $35K | 12K |
| 2024-02-25 | Nance Mark E | General Counsel | Grant | 22K | $0.00 | $0 | 58K |
| 2024-02-25 | Nance Mark E | General Counsel | Tax withholding | 3K | $22.65 | $59K | 36K |
| 2024-02-25 | Kaabi Faez C | Chief Accounting Officer | Tax withholding | 2K | $22.65 | $34K | 14K |
| 2024-02-25 | Kaabi Faez C | Chief Accounting Officer | Grant | 31K | $0.00 | $0 | 45K |
| 2024-02-15 | Hulit Barbara B. | Director | Grant | 22K | $0.00 | $0 | 35K |
| 2023-11-16 | Conley Eric | SVP, Orthodontics | Buy | 2K | $22.89 | $50K | 47K |
| 2023-11-16 | Conley Eric | SVP, Orthodontics | Buy | 1 | $22.90 | $23 | 47K |
| 2023-11-16 | Conley Eric | SVP, Orthodontics | Buy | 2 | $22.90 | $46 | 47K |
| 2023-11-08 | Nance Mark E | General Counsel | Buy | 5K | $21.75 | $109K | 39K |
| 2023-11-06 | Keller Stephen | Principal Financial Officer | Buy | 2K | $21.53 | $43K | 13K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for NVST worth $510K at the prices reported; 1 in the last 90 days worth $220K. Latest: Reis Mischa filed on 2026-08-20 to sell 8,000 shares ($220K) from 2026-08-20.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-20 | Reis MischaOfficer | 8K | $220K | 0.005% | 2026-08-20 | Fidelity Brokerage Services LLC |
| 2026-02-10 | Reis MischaOfficer | 10K | $290K | 0.006% | 2026-02-10 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of NVST in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 5.2% of the class (8,574,557 shares), filed 2026-04-29 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-11 | 13G/Ano. 7 | Morgan Stanleyparent holding company, corporation | 7.1M | 4.4% | 2026-03-31 |
| 2026-05-11 | 13G/Ano. 7 | Atlanta Capital Management Company, LLCinvestment adviser, corporation | 6.0M | 3.7% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 8.6M | 5.2% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-01-29 | 13G/Ano. 1 | Franklin Mutual Advisers, LLCinvestment adviser, other entity | 8.0M | 4.8% | 2025-12-31 |
13F holders
Tracked managers holding NVST at their latest 13F. JSON8 of the 30 tracked managers held NVST at their latest 13F, $229.7M in total at quarter-end prices. AQR Capital Management is the largest at $106.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 4.0M | $106.0M | 0.04% | +1.4M |
| Point72 Asset Management | 2026-06-30 | 1.6M | $41.2M | 0.05% | new |
| Renaissance Technologies | 2026-06-30 | 1.5M | $40.1M | 0.06% | +312K |
| Millennium Management | 2026-06-30 | 1.1M | $30.2M | 0.01% | new |
| D. E. Shaw & Co. | 2026-06-30 | 229K | $6.0M | 0.00% | +211K |
| Two Sigma Investments | 2026-06-30 | 135K | $3.5M | 0.00% | +9K |
| Citadel Advisors | 2026-06-30 | 57K | $1.5M | 0.00% | -4.5M |
| Bridgewater Associates | 2026-06-30 | 42K | $1.1M | 0.00% | -35K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-07-03) Envista Holdings reported revenue of $730.5M, up 7.1% from the same quarter a year earlier, and net income of $53.7M (0.33 diluted EPS). In FY 2025 it generated $275.7M of operating cash flow. As of 2026-07-03, cash was $1.13B against $1.44B of debt.
- Cash
- $1.13B
- Debt
- $1.44B
- Equity
- $3.08B
- Total assets
- $5.60B
- Shares outstanding
- 160,617,709
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-07-03 | $730.5M | $53.7M | 7.4% | 0.33 |
| Q1 FY 2026 | 2026-04-03 | $705.5M | $38.7M | 5.5% | 0.23 |
| Q4 FY 2025derived | 2025-12-31 | $750.6M | $32.9M | 4.4% | n/a |
| Q3 FY 2025 | 2025-09-26 | $669.9M | -$30.3M | -4.5% | -0.18 |
| Q2 FY 2025 | 2025-06-27 | $682.1M | $26.4M | 3.9% | 0.16 |
| Q1 FY 2025 | 2025-03-28 | $616.9M | $18.0M | 2.9% | 0.10 |
| Q4 FY 2024derived | 2024-12-31 | $652.9M | $1.2M | 0.2% | n/a |
| Q3 FY 2024 | 2024-09-27 | $601.0M | $8.2M | 1.4% | 0.05 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2.72B | $47.0M | $275.7M | $45.3M | n/a | n/a |
| FY 2024 | 2024-12-31 | $2.51B | -$1.12B | $336.5M | $33.8M | n/a | n/a |
| FY 2023 | 2023-12-31 | $2.57B | -$100.2M | $275.7M | $58.2M | n/a | n/a |
| FY 2022 | 2022-12-31 | $2.57B | $243.1M | $182.7M | $75.7M | n/a | n/a |
| FY 2021 | 2021-12-31 | $2.51B | $340.5M | $361.6M | $54.7M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-07-03; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Envista Holdings in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Envista Holdings (NVST), SEC CIK 1757073, listed on NYSE, classified by the SEC as dental equipment & supplies. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-25.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-20.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-11.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-07-03.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-25.JSON and CSV
- Company record
- EDGAR filing index for CIK 1757073Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as dental equipment & supplies
Other company pages
- MLMMartin Marietta Materials
- MMM3M
- MNSTMonster Beverage
- MOAltria Group
- MODModine Manufacturing
- MOSMosaic
- MPMP Materials
- MPCMarathon Petroleum
- MPWRMonolithic Power Systems
- MRKMerck
- MRNAModerna
- MRSHMarsh & McLennan Companies
- MRVLMarvell Technology
- MSMorgan Stanley
- MSCIMSCI
- MSFTMicrosoft
- MSIMotorola Solutions
- MSTRStrategy
- MTBM&T Bank
- MTCHMatch Group
- MTDMettler-Toledo International
- MTNVail Resorts
Datasets
Frequently Asked Questions
How much of NVST is sold short?
12,072,597 shares were held short at the 2026-09-30 settlement, 3.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is NVST's daily short volume?
On 2026-10-23, 475,477 of the 1,103,482 NVST shares reported to FINRA were sold short, 43.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does NVST have fails to deliver?
The SEC's latest file shows 4,741 NVST shares failed to deliver at settlement 2026-09-25. Fails are reported per settlement date and published twice a month with a lag.
Are NVST insiders buying or selling?
Insiders at NVST reported 1 open-market sell worth $220K in the last 90 days and no open-market buys. Latest filing: Nilsson Stefan (President, Nobel Biocare) on 2026-08-25.
Have NVST insiders filed to sell?
2 Form 144 notices on file for NVST worth $510K at the prices reported; 1 in the last 90 days worth $220K. Latest: Reis Mischa filed on 2026-08-20 to sell 8,000 shares ($220K) from 2026-08-20.
Who owns 5% or more of NVST?
1 holder reports 5% or more of NVST in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 5.2% of the class (8,574,557 shares), filed 2026-04-29 for an event on 2026-03-31.
What did NVST report last quarter?
In Q2 FY 2026 (quarter ended 2026-07-03) Envista Holdings reported revenue of $730.5M, up 7.1% from the same quarter a year earlier, and net income of $53.7M (0.33 diluted EPS). In FY 2025 it generated $275.7M of operating cash flow. As of 2026-07-03, cash was $1.13B against $1.44B of debt.
Which tracked 13F managers own NVST?
8 of the 30 tracked 13F managers held NVST shares at their latest filing, $229.7M in all. The largest: Cliff Asness's AQR Capital Management (4.0M shares, $106.0M), Steve Cohen's Point72 Asset Management (1.6M shares, $41.2M), Renaissance Technologies (1.5M shares, $40.1M), Izzy Englander's Millennium Management (1.1M shares, $30.2M), D. E. Shaw & Co. (229K shares, $6.0M), Two Sigma Investments (135K shares, $3.5M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.